Skip to main content
SpringerLink
Log in

Estimation of the Release Time from Isolation for Patients with Differentiated Thyroid Cancer Treated with High-dose I-131

  • Original Article
  • Published:
Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

Patients receiving high-dose I-131 to treat differentiated thyroid cancer are isolated from visitors to limit radiation exposure to reasonable levels. The appropriate isolation time is unclear and has not been reported in Korea. The purpose of this study was to estimate the isolation time and investigate the possibility of earlier release from isolation.

Methods

This study was a retrospective analysis of data from 71 patients (10 men and 61 women; mean age, 49 ± 11.1 y) who received 3.7 GBq (47 patients), 5.55 GBq (23 patients), or 7.4 GBq (1 patient) of I-131 between January 2008 and December 2008. The radiation dose was measured with a fixed probe placed inside the isolation room. The total estimated dose equivalent (TEDE) to family members, the time required for the external dose rate to become <0.07 mSv/h, and the time required for whole-body retention to become <1.2 GBq were calculated.

Results

By the TEDE criterion (<5 mSv), 70 of 71 patients (98.6%) could have been released without isolation. By the external dose rate criterion, 10 of 71 (14.1%) and 60 of 71 patients (84.5%) could have been released without isolation and within 24 h, respectively. With whole-body retention criterion, 19 of 71 (26.8%) and 48 of 71 patients (67.6%) could have been released within 24 h and within 48 h, respectively.

Conclusions

Appropriate release times were estimated and compared using different criteria. Most patients could have been released without isolation or within 24 h of radiation treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. US Nuclear Regulatory Commission (1997) Release of patients administered radioactive materials. Regulatory guide 8.39. United States Nuclear Regulatory Commission, Washington DC

  2. Choi YJ, Park YL, Koh JH (2008) Prevalence of thyroid cancer at a medical screening center: pathological features of screen-detected thyroid carcinomas. Yonsei Med J 49:748–756

    Article  PubMed  Google Scholar 

  3. Kang HW, No JH, Chung JH, Min YK, Lee MS, Lee MK et al (2004) Prevalence, clinical and ultrasonographic characteristics of thyroid incidentalomas. Thyroid 14:29–33

    Article  PubMed  Google Scholar 

  4. Park SG (2008) Effective half-life of I-131 in patients with differentiated thyroid cancer. Nucl Med Mol Imaging 42:464–468

    Google Scholar 

  5. Park HM, Jang JW, Yang HC, Kim YG (2007) Outpatient radioablation therapy for thyroid cancer patients with minimal radiation exposure to the family members. Nucl Med Mol Imaging 41:218–225

    Google Scholar 

  6. Venencia CD, Germanier AG, Bustos SR, Giovannini AA, Wyse EP (2002) Hospital discharge of patients with thyroid carcinoma treated with 131I. J Nucl Med 43:61–65

    CAS  PubMed  Google Scholar 

  7. Barrington SF, Kettle AG, O’Doherty MJ, Wells CP, Somer EJR, Coakley AJ (1996) Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid. Eur J Nucl Med 23:123–130

    Article  CAS  PubMed  Google Scholar 

  8. Pant GS, Sharma SK, Bal CS, Rakesh K, Rath GK (2006) Radiation dose to family member of hyperthyroidism and thyroid cancer patients treated with 131I. Radiat Prot Dosim 118:22–27

    Article  CAS  Google Scholar 

  9. Rutar FJ, Augustine SC, Colcher D, Siegel JA, Jacobson DA, Tempero MA et al (2001) Outpatient treatment with (131)I-anti-B1 antibody: radiation exposure to family members. J Nucl Med 42:907–915

    CAS  PubMed  Google Scholar 

  10. Remy H, Borget I, Leboullex S, Guilbert N, Lavielle F, Garsi J et al (2008) 131I effective half-life and dosimetry in thyroid cancer patients. J Nucl Med 49:1445–1450

    Article  CAS  PubMed  Google Scholar 

  11. Pacilio M, Bianciardi L, Panichelli V, Argiro G, Ciprani C (2005) Management of 131I therapy for thyroid cancer. Nucl Med Commun 26:623–631

    Article  PubMed  Google Scholar 

  12. Rosario PW, Borges MA, Purish S (2008) Preparation with recombinant human thyroid-stimulation hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med 49:1776–1782

    Article  PubMed  Google Scholar 

  13. Matovic MD, Jancovic SM, Jeremic M, Tasic Z, Vlajkovic M (2009) Unexpected effect of furosemide on radioiodine urinary excretion in patients with differentiated thyroid carcinoma treated with iodine 131. Thyroid 19:843–848

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, College of Medicine, Dankook University, Dandae-Ro 191, Dongnam-Gu, Cheonan-Si, Chungnam-Do, 330-180, Korea

    Jai Hyuen Lee & Seok Gun Park

Authors
  1. Jai Hyuen Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seok Gun Park
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seok Gun Park.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, J.H., Park, S.G. Estimation of the Release Time from Isolation for Patients with Differentiated Thyroid Cancer Treated with High-dose I-131. Nucl Med Mol Imaging 44, 241–245 (2010). https://doi.org/10.1007/s13139-010-0041-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13139-010-0041-0

Keywords

Search

Navigation